July 11, 2016
AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)
- DIPG are highly aggressive and difficult to treat brain tumors found at the base of the brain
- Marks the first FDA Rare Pediatric Designation for an AbbVie investigational medicine
- In 2014, the FDA and European Medicines Agency granted ABT-414 Orphan Drug Designation for the treatment of glioblastoma and glioma in adults, respectively

NORTH CHICAGO, Ill., July 11, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation for ABT-414, an investigational antibody drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), for the treatment of pediatric patients with EGFR-amplified Diffuse Intrinsic Pontine Glioma (DIPG), known to be highly aggressive and difficult to treat brain tumors found at the base of the brain.1

Though brainstem tumors are extremely rare among adults, they comprise approximately 10-15 percent of all pediatric brain tumors. DIPG is the most common subtype of tumor in this anatomical region and the second most common malignant brain tumor of childhood, with an estimated 200-400 children affected each year in the United States.2,3,8  

The FDA granted the Rare Pediatric Disease Designation based on a proposed pediatric sub-study "nested" within the ongoing Phase 2 study of ABT-414 in adults with recurrent EGFR-amplified glioblastoma, conducted in collaboration with the European Organization for Research and Treatment of Cancer (EORTC).4,5 

"Pediatric patients with high grade gliomas have a rare and fatal disease.2 This Rare Pediatric Designation, a first for AbbVie, is an important advancement as we continue to evaluate ABT-414 and its potential to help this group of patients who desperately need a new treatment option," said Gary Gordon, M.D., vice president, oncology clinical development, AbbVie. "The proposal of including a nested cohort within an adult global trial is an endeavor that we hope may bring more treatments to pediatric patients."

About ABT-414
ABT-414 is an investigational monoclonal antibody drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR) developed by AbbVie researchers with components in-licensed from Life Science Pharmaceuticals, Inc. and Seattle Genetics.6 AbbVie is evaluating it for the treatment of adult patients with EGFR-amplified glioblastoma, an aggressive malignant primary brain tumor.6,7 In 2014, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency granted Orphan Drug Designation for the treatment of adult glioblastoma and glioma, respectively.4,5 In 2016, the FDA granted Rare Disease Designation to ABT-414 for the treatment of pediatric patients with EGFR-amplified Diffuse Intrinsic Pontine Gliomas (DIPG). ABT-414 is an investigational compound and its efficacy and safety have not been established by the FDA or any other health authority.

About Pediatric High Grade Gliomas
Diffuse Intrinsic Pontine Glioma (DIPG) is a type of high grade glioma (HGG).8 HGG represents one of the most common central nervous system (CNS) tumors among adults; however, they comprise only approximately 8-12 percent of all CNS tumors in pediatric patients.2 Pediatric HGG are highly aggressive tumors that account for a significant amount of morbidity and mortality among children.2 Despite numerous treatment approaches, five-year survival outcomes range from 15-35 percent and the majority of children succumb to their disease.2,9

About Glioblastoma
Glioblastoma is the most common and most aggressive type of malignant primary brain tumor.7 Prior to diagnosis, patients may experience headache, vision problems, nausea/vomiting, personality changes and seizures.7 For adults with more aggressive glioblastoma, treated with concurrent Temozolamide and radiation therapy, median survival is about 14.6 months.9 Treatment for glioblastoma remains challenging.7 Standard treatment is surgical resection, radiotherapy and concomitant adjunctive chemotherapy.9

About AbbVie in Oncology
AbbVie is striving to outsmart cancer by working with scientists, physicians, industry peers, patient advocacy groups and most importantly patients, to discover, develop and provide new therapies that will have a remarkable impact on the lives of people around the world affected by cancer. Our goal is to provide medicines that make a transformational improvement in cancer treatment and outcomes for cancer patients. By exploring and investing in new pathways, technologies and approaches, AbbVie is breaking ground in some of the most widespread and difficult-to-treat cancers. We are also exploring solutions to help patients obtain access to our cancer medicines. With the acquisition of Pharmacyclics in 2015 and Stemcentrx in 2016, and through several collaborations, AbbVie's oncology portfolio consists of marketed medicines and a pipeline containing multiple new molecules being evaluated worldwide in nearly two hundred clinical trials in 20 different tumor types. For more information about AbbVie Oncology, please visit

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in AbbVie's 2015 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

1 Warren, K.E., Diffuse intrinsic pontine glioma: poised for progress. Front Oncol. 2012; 2: 205.
2 Fangusaro, J. Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol. 2012; 2: 105.
3 Central Brain Tumor Registry of the United States (2010) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006 (Central Brain Tumor Registry of the United States, Hinsdale, IL).
4 U.S. Food and Drug Administration (2014). Orphan Drug Designations and Approvals. Accessed May 17 2016.
5 European Medicines Agency (2014). Public summary of opinion of orphan designation. Accessed May 17, 2016.
6 Van Den Bent, M et al. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM). Poster presentation #2542; presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, June 5, 2016.
7 Omuro, A. & DeAngelis, L. Glioblastoma and Other Malignant Gliomas: A Clinical Review. JAMA. 2013;310(17):1842-1850.
8 MacDonald, T.J., Aguilera, D., & Kramm, C.M. Treatment of high-grade glioma in children and adolescents. Neuro-Oncology. 2011; 13(10): 1049–1058.
9 American Brain Tumor Association (2014). Glioblastoma (GBM). Accessed on May 17, 2016.

AbbVie logo

Logo -


For further information: AbbVie U.S. Media: Jack Hirschfield,, (224) 458-0943; AbbVie Global Media: Dave Freundel,, (224) 358-6576; Investors: Liz Shea,, (847) 935-2211



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?